Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Risk adjusted net present value: What is the current valuation of Tyra Biosciences's TYRA-300?
TYRA-300 is a small molecule commercialized by Tyra Biosciences, with a leading Phase II program in Metastatic Transitional (Urothelial) Tract...